Valaciclovir for Epstein-Barr virus suppression in Chronic Obstructive Pulmonary Disease: A Randomised Controlled Trial (EViSCO)
D. Linden (Belfast, United Kingdom), H. Guo-Parke (Belfast, United Kingdom), M. Mckelvey (Belfast, United Kingdom), G. Einarsson (Belfast, United Kingdom), A. Lee (Belfast, United Kingdom), D. Fairley (Belfast, United Kingdom), V. Brown (Belfast, United Kingdom), D. Logan (Belfast, United Kingdom), C. Campbell (Belfast, United Kingdom), D. Singh (Manchester, United Kingdom), M. Tunney (Belfast, United Kingdom), D. Mcauley (Belfast, United Kingdom), C. Taggart (Belfast, United Kingdom), J. Kidney (Belfast, United Kingdom)
Source: International Congress 2022 – Pleural and other respiratory infections
Session: Pleural and other respiratory infections
Session type: Thematic Poster
Number: 1104
 
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Linden (Belfast, United Kingdom), H. Guo-Parke (Belfast, United Kingdom), M. Mckelvey (Belfast, United Kingdom), G. Einarsson (Belfast, United Kingdom), A. Lee (Belfast, United Kingdom), D. Fairley (Belfast, United Kingdom), V. Brown (Belfast, United Kingdom), D. Logan (Belfast, United Kingdom), C. Campbell (Belfast, United Kingdom), D. Singh (Manchester, United Kingdom), M. Tunney (Belfast, United Kingdom), D. Mcauley (Belfast, United Kingdom), C. Taggart (Belfast, United Kingdom), J. Kidney (Belfast, United Kingdom). Valaciclovir for Epstein-Barr virus suppression in Chronic Obstructive Pulmonary Disease: A Randomised Controlled Trial (EViSCO). 1104
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|